Search

Crinecerfont

[A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993] … [A264818] The majority of the poor health outcomes in patients with CAH result from the inability to precisely titrate glucocorticoid dosages to both adequately replace the deficiency and sufficiently

Beractant

Administration of lung surfactant remains the cornerstone of therapy in this condition that is currently the leading cause of death in preterm infants. … It is suspended in 0.9% sodium chloride solution, and heat-sterilized.

Anisindione

Anisindione is a synthetic anticoagulant and an indanedione derivative. … II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver.

Ospemifene

FDA approved on February 26, 2013.

Thyroid, porcine

[A190813] Thyroid extracts were never FDA approved as their use in the United States predates the FDA.[A190831] … [A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891[A190807] but its use dates back as far as the 6th century.

Dichromate

Phenyl trimethicone

Vilanterol

[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020. … Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.

Benzethonium

It is additionally found in cosmetics and toiletries such as mouthwashes and anti-itch ointments. … It is shown to be effective in mediating its antimicrobial action against bacteria, fungi, mold and viruses.

Vilobelimab

[L45839] In April 2023, the FDA issued an emergency use authorization (EUA) for vilobelimab for the treatment of COVID-19 in hospitalized adults requiring mechanical ventilation or artificial life support